View Older Stories View More Recent Stories

Jun 29, 2021 08:10PM Form 3 INTEGRAL AD SCIENCE HOLD For: Jun 29 Filed by: Atlas Venture Associates VIII, Inc.
Jun 28, 2021 04:57PM Form 4 Generation Bio Co. For: Jun 24 Filed by: Atlas Venture Associates Opportunity I, LLC
Jun 23, 2021 08:27PM Form 4 Generation Bio Co. For: Jun 21 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Jun 22, 2021 07:00AM Vedere Bio II Announces Appointment of Gabor Veres, Ph.D., as Chief Scientific Officer
Jun 21, 2021 04:51PM Form 4 Generation Bio Co. For: Jun 16 Filed by: Atlas Venture Fund X, L.P.
Jun 17, 2021 04:16PM TCW Special Purpose Acquisition Corp. (TSPQ) Appoints David W. Rye to its Board
Jun 17, 2021 04:15PM TCW Special Purpose Acquisition Corp. Appoints David W. Rye to Board of Directors
Jun 2, 2021 06:41PM Form 4 Day One Biopharmaceutica For: Feb 01 Filed by: Atlas Venture Associates XI, LLC
Jun 2, 2021 09:00AM Harvard Business School Announces Its 2021-2022 Blavatnik Fellows
May 26, 2021 09:56PM Form 3 Day One Biopharmaceutica For: May 26 Filed by: Atlas Venture Fund XI, L.P.
May 18, 2021 06:17PM Form 4 Kymera Therapeutics, For: May 18 Filed by: Atlas Venture Fund X, L.P.
May 18, 2021 07:00AM Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies
May 14, 2021 10:39AM Form 13F-HR Atlas Venture Advisors, For: Mar 31
May 14, 2021 10:39AM Form 13F-NT Atlas Venture Associates For: Mar 31
May 14, 2021 10:38AM Form 13F-HR Atlas Venture Associates For: Mar 31
May 14, 2021 10:37AM Form 13F-NT ATLAS VENTURE FUND VI For: Mar 31
May 14, 2021 10:36AM Form 13F-NT Atlas Venture Associates For: Mar 31
May 10, 2021 07:00AM Atlas Venture Welcomes Samantha Truex as Venture Partner
May 3, 2021 06:30AM Affinia Therapeutics Closes $110 Million Series B Financing
Apr 27, 2021 04:04PM Triplet Therapeutics Presents Preclinical Data for TTX-3360, Announces Equity Pledge at the CHDI Foundation’s 16th Annual HD Therapeutics Conference
Apr 20, 2021 08:45AM Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer
Apr 20, 2021 07:00AM Vividion Therapeutics Expands Leadership Team with Key Regulatory and CMC Appointments
Apr 15, 2021 02:00AM Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
Apr 15, 2021 02:00AM Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
Apr 14, 2021 08:19PM Form 4 Generation Bio Co. For: Apr 12 Filed by: Atlas Venture Associates X, LLC
Apr 9, 2021 08:54PM Form 4 Generation Bio Co. For: Apr 07 Filed by: Atlas Venture Associates X, LLC
Apr 1, 2021 06:16PM Form 4 Ikena Oncology, Inc. For: Mar 30 Filed by: Atlas Venture Associates XI, LLC
Mar 25, 2021 08:09PM Form 3 Ikena Oncology, Inc. For: Mar 25 Filed by: Atlas Venture Fund X, L.P.
Mar 25, 2021 07:00AM Arkuda Therapeutics to Participate in Stifel's 3rd Annual CNS Day
Mar 24, 2021 09:29AM Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
Mar 24, 2021 09:29AM Fulcrum Therapeutics Appoints Judith A. Dunn, Ph.D. as President of Research and Development
Mar 18, 2021 05:08PM Form 4 Generation Bio Co. For: Mar 16 Filed by: Atlas Venture Fund X, L.P.
Mar 18, 2021 07:57AM Delix Therapeutics Names Mark Rus as Chief Executive Officer
Mar 16, 2021 07:38PM Form 4 Kymera Therapeutics, For: Mar 12 Filed by: Atlas Venture Associates X, LLC
Mar 16, 2021 07:00AM Remix Therapeutics Appoints Matthew R. Patterson as Executive Chairman of its Board of Directors
Mar 9, 2021 07:00AM Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer
Mar 5, 2021 07:00AM Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at Upcoming Conferences
Feb 24, 2021 06:00AM Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
Feb 22, 2021 04:59PM Form 4 Kymera Therapeutics, For: Feb 18 Filed by: Atlas Venture Fund X, L.P.
Feb 17, 2021 08:27AM Form SC 13D/A Magenta Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 06:15PM Form 4 Magenta Therapeutics, For: Feb 11 Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 05:40PM Form SC 13D/A Spero Therapeutics, Inc. Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 05:38PM Form SC 13G Generation Bio Co. Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 05:38PM Form SC 13G/A Akero Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 16, 2021 05:34PM Form SC 13D Gemini Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 16, 2021 05:33PM Form SC 13G Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Feb 16, 2021 05:32PM Form SC 13G Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Feb 11, 2021 01:48PM Form 3 Gemini Therapeutics, For: Feb 05 Filed by: Atlas Venture Associates XII, L.P.
Feb 11, 2021 11:16AM Form 13F-HR/A Atlas Venture Associates For: Dec 31
Feb 10, 2021 06:30AM Day One Announces $130 Million Series B Financing to Accelerate New Targeted Cancer Treatments for Children
View More Recent Stories View Older Stories